TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22733953

Group type: EXPERIMENTAL
Intervention: Risedronate treatment from one week after surgery (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Risedronate treatment from one month after surgery (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Risedronate treatment from three months after surgery (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention timing mentioned)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Functional outcomes at one year after surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Incidence of complications
Number of subjects: 90
Study: 21203736

Group type: EXPERIMENTAL
Intervention: Presence of impaction (Group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Absence of impaction (Group 2)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mandibular length
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Difference between alveolar arch length and total teeth size
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combined prediction from both factors
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 83
Study: 17391167

Group type: EXPERIMENTAL
Intervention: Insulin monotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Insulin and metformin up to 2000 mg daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Insulin and pioglitazone 30 mg daily
Number of subjects: 57
Study: 15713724

Group type: EXPERIMENTAL
Intervention: Oral Testosterone (T) 200, 400, or 800 mg in sesame oil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral Testosterone Enanthate (TE) 200, 400, or 800 mg in sesame oil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral Testosterone (T) 200, 400, or 800 mg in sesame oil with Dutasteride (D)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral Testosterone Enanthate (TE) 200, 400, or 800 mg in sesame oil with Dutasteride (D)
Number of subjects: 13
Study: 11999596

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 30
Study: 9793363

Group type: EXPERIMENTAL
Intervention: Glass-ionomer systems with dental dike and varnish
Number of subjects: 0

Group type: COMPARATOR
Intervention: Five ionomeric products
Number of subjects: 0
Study: 7890497

Group type: EXPERIMENTAL
Intervention: Monocular acuity norms using the acuity card procedure (ACP) and Teller Acuity Cards (TAC)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Monocular acuity tests
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Interocular acuity difference
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Acuities obtained by the same tester on different days and by different testers on the same day
Number of subjects: 460
Study: 2111982

Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody (replacing cyclosporine during the first postoperative week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional immunosuppression (cyclosporine, azathioprine, and steroids)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional immunosuppression
Number of subjects: 79
Study: 296397

Group type: EXPERIMENTAL
Intervention: 0.3% tiodonium chloride mouthrinse
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 55
Study: 31728673

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day prednisone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg/day prednisone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day prednisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cumulative prednisone dose for 2 mg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dose for 1.5 mg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dose for 1 mg/kg/day
Number of subjects: 30
Study: 31099599

Group type: EXPERIMENTAL
Intervention: MacConkey agar medium supplemented with 8 mg/L of ceftiofur (MC-CEF)
Number of subjects: 773

Group type: COMPARATOR
Intervention: Randomly selected E. coli (RSEC)
Number of subjects: 773
Study: 25526873

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping with cord stripping (test arm)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed cord clamping (control arm)
Number of subjects: 67
Study: 23415615

Group type: EXPERIMENTAL
Intervention: Heel lance treated with sucrose and non‐nutritive sucking
Number of subjects: 131

Group type: COMPARATOR
Intervention: Heel lance treated with placebo and non‐nutritive sucking
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study: 20876366

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-diuretic antihypertensive treatment (Control)
Number of subjects: 40
Study: 18647431

Group type: EXPERIMENTAL
Intervention: School-based food garden intervention
Number of subjects: 252
Study: 17202205

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Photodynamic therapy associated with systemic steroids (SS + PDT)
Number of subjects: 20
Study: 14976306

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 11323577

Group type: EXPERIMENTAL
Intervention: Unilateral hepatic duct drainage (group A)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Bilateral hepatic duct drainage (group B)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 157
Study: 9460279

Group type: EXPERIMENTAL
Intervention: One mammary artery
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Two mammary arteries
Number of subjects: 216
Study: 8194502

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (two types)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Caffeinated coffee
Number of subjects: 119
Study: 2886822

Group type: EXPERIMENTAL
Intervention: Blood glucose maintained at 3.2 mmol/l
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blood glucose maintained at 2.5 mmol/l for 30 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Blood glucose raised to 4.5 mmol/l
Number of subjects: 25
Study: 29852078

Group type: EXPERIMENTAL
Intervention: Graded exercise test (4-min stages)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short continuous exercise sessions (SCEequal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Graded exercise test
Number of subjects: 15
Study: 28607897

Group type: EXPERIMENTAL
Intervention: Two layers pharyngeal repair
Number of subjects: 21

Group type: COMPARATOR
Intervention: Three layers pharyngeal repair
Number of subjects: 21
Study: 26037024

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Esophagectomy (MIE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Esophagectomy (OE)
Number of subjects: 0
Study: 23009573

Group type: EXPERIMENTAL
Intervention: Classical music during procedure (Group II)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No music (Group I)
Number of subjects: 70
Study: 20538327

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (defined as 25-hydroxyvitamin D level of 30 ng/mL or less)
Number of subjects: 1024
Study: 18160303

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1‐8)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Docetaxel (35 mg/m2 days 1‐8‐15)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 101

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 101
Study: 16169319

Group type: EXPERIMENTAL
Intervention: Eplerenone (100-200 mg/d)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Losartan (50-100 mg/d)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Eplerenone and Losartan
Number of subjects: 168
Study: 12896935

Group type: EXPERIMENTAL
Intervention: 24,000 IU oral vitamin A on days 1 and 2 after delivery
Number of subjects: 11619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11619
Study: 10587773

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions for people after suicide attempts
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Principles of care after a suicide attempt
Number of subjects: 10
Study: 8671908

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1660550

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (5%, 10%, and 20% of the pressor dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 6751131

Group type: EXPERIMENTAL
Intervention: Abstinence-oriented insight group therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Controlled drinking-oriented behavioral modification group therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 31743822

Group type: EXPERIMENTAL
Intervention: Grinding (Gr)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Grinding + Polishing (Gr + Pol)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Grinding + Glaze (Gr + Gl)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Grinding + Polishing + Glaze (Gr + Pol + Gl)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (Ctrl) - as-sintered
Number of subjects: 5
Study: 31652034

Group type: EXPERIMENTAL
Intervention: McGrath MAC X-Blade videolaryngoscope
Number of subjects: 80
Study: 28598681

Group type: EXPERIMENTAL
Intervention: methotrexate and adalimumab (ADA)
Number of subjects: 155

Group type: COMPARATOR
Intervention: methotrexate and placebo (PLA)
Number of subjects: 155
Study: 26218411

Group type: COMPARATOR
Intervention: Standard of care (SoC, 3 pretreatment education sessions)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: SoC and automated text reminders if dosing >30 minutes late
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (SoC)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Intervention group (SoC + text reminders)
Number of subjects: 230
Study: 23539462

Group type: EXPERIMENTAL
Intervention: Modified sutureless manual small-incision cataract surgery (M-MSICS)
Number of subjects: 21
Study: 21346207

Group type: EXPERIMENTAL
Intervention: Low spatial frequency (SF) grating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High spatial frequency (SF) grating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filter-rectify-normalize-filter model (extended FRF model)
Number of subjects: 0
Study: 19496102

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 50
Study: 17535864

Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg s.c.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.083 mg/kg s.c.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg i.m.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhGH administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IGFBP-3 concentrations
Number of subjects: 20
Study: 15510886

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with phentanyl (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine appropriate for the need of the patient (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both methods of analgesia
Number of subjects: 60
Study: 11564024

Group type: EXPERIMENTAL
Intervention: Easicath
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lofric
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Aquacath
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Silky
Number of subjects: 61
Study: 9624225

Group type: EXPERIMENTAL
Intervention: Low sodium intake (80 mmol/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High sodium intake (180 mmol/d)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both interventions (80 and 180 mmol/d)
Number of subjects: 29
Study: 7827853

Group type: EXPERIMENTAL
Intervention: Intermittent low-friction self-catheterization (ILSC) for more than 12 months
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intermittent low-friction self-catheterization (ILSC) for 6 months
Number of subjects: 101
Study: 3371886

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 154
Study: 31769337

Group type: EXPERIMENTAL
Intervention: Daily functional electrostimulation group (DFEG; n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-daily functional electrostimulation group (TFEG; n = 17)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group (CG; n = 16)
Number of subjects: 48
Study: 29886113

Group type: EXPERIMENTAL
Intervention: Intralesional verapamil (2.5 mg/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (40 mg/mL)
Number of subjects: 50
Study: 28640988

Group type: EXPERIMENTAL
Intervention: ORAL paliperidone
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: PP1M
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: PP3M
Number of subjects: 449
Study: 26357940

Group type: EXPERIMENTAL
Intervention: AFN-1252 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 200 mg (twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 400 mg (twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 600 mg (total daily dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AFN-1252 800 mg (total daily dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23159479

Group type: EXPERIMENTAL
Intervention: 16 IU of intranasal oxytocin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22004305

Group type: EXPERIMENTAL
Intervention: Middle School Success intervention (MSS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular foster care control
Number of subjects: 100
Study: 18507895

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 16552801

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR oral administration at the dose of 800‐1200 mg/d for 3 ‐ 5 d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 500 mg 5‐FU + 200 mg/d CF by venous drip for 3 ‐ 5 d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 14586743

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (0.5 mg/kg per day of prednisolone)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Warfarin monotherapy
Number of subjects: 15
Study: 10756223

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (as-needed usage)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 9161190

Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Concise White Sealant)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Light-cured resin-reinforced glass-ionomer cement (Vitrebond)
Number of subjects: 53
Study: 1563463

Group type: EXPERIMENTAL
Intervention: Lisuride subcutaneous infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TRH test (200 micrograms i.v.)
Number of subjects: 8
Study: 3909544

Group type: EXPERIMENTAL
Intervention: Acyclovir ophthalmic ointment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (Acyclovir ointment and Oral acyclovir)
Number of subjects: 29
Study: 30466338

Group type: EXPERIMENTAL
Intervention: Education-based safe-transport program (Behind the Wheel)
Number of subjects: 190
Study: 30284023

Group type: EXPERIMENTAL
Intervention: Lisinopril monotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lisinopril and losartan combination therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 63
Study: 27894058

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure via home-based telehealth (PE-HBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Prolonged Exposure via in-person (PE-IP)
Number of subjects: 132
Study: 24571062

Group type: EXPERIMENTAL
Intervention: gabapentin/ketamine/lornoxicam/ropivacaine
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: gabapentin/placebo/placebo/placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: placebo/placebo/lornoxicam/placebo
Number of subjects: 148

Group type: COMPARATOR
Intervention: placebo/placebo/placebo/placebo
Number of subjects: 148
Study: 23188130

Group type: EXPERIMENTAL
Intervention: ARB combined with QYHJ
Number of subjects: 108

Group type: COMPARATOR
Intervention: ARB
Number of subjects: 108
Study: 21194898

Group type: EXPERIMENTAL
Intervention: GR205171 (N=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (N=19)
Number of subjects: 39
Study: 19416259

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1) (Xamiol) - once daily
Number of subjects: 312

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg mL(‐1) scalp solution - twice daily
Number of subjects: 312
Study: 18001533

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg + amlodipine + benazepril
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + amlodipine + benazepril
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (amlodipine + benazepril)
Number of subjects: 151
Study: 15346659

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil 50 mg
Number of subjects: 32
Study: 11799002

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency devices
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monopolar radiofrequency device
Number of subjects: 22
Study: 9587047

Group type: EXPERIMENTAL
Intervention: Neoplanta capsule
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sandimmune Neoral capsule
Number of subjects: 24
Study: 7905217

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Log IC90 and CD4+ count
Number of subjects: 35
Study: 3152946

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium after cisplatin administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous magnesium before and after cisplatin administration
Number of subjects: 28
Study: 15692311

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 31797677

Group type: EXPERIMENTAL
Intervention: DMPA-IM (Depo-medroxyprogesterone acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper-intrauterine device (IUD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no contraception or infrequent condom use)
Number of subjects: 0
Study: 31758738

Group type: EXPERIMENTAL
Intervention: MRI-ERSPC-3/4
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Radtke's RM
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Distler's RM
Number of subjects: 307
Study: 27001344

Group type: EXPERIMENTAL
Intervention: Metabolic response after neoadjuvant CRT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Stable disease after neoadjuvant CRT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Progression after neoadjuvant CRT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Relative change in FDG uptake after 14 days of CRT
Number of subjects: 106
Study: 25310825

Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sober (control)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low conflict
Number of subjects: 131
Study: 23136231

Group type: EXPERIMENTAL
Intervention: DD-MVAC (M 30 mg/m(2), V 3 mg/m(2), A 30 mg/m(2), C 70 mg/m(2) q 2 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: DD-GC (G 2500 mg/m(2), C 70 mg/m(2) q 2 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: DD-GC
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: DD-MVAC
Number of subjects: 130
Study: 22177374

Group type: EXPERIMENTAL
Intervention: Intravenous MID administration
Number of subjects: 73

Group type: COMPARATOR
Intervention: Oral MID administration
Number of subjects: 73

Group type: COMPARATOR
Intervention: Overall CYP3A activity
Number of subjects: 73
Study: 19226044

Group type: EXPERIMENTAL
Intervention: Perioperative cell salvage
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 154

Group type: COMPARATOR
Intervention: Allogeneic blood alone
Number of subjects: 154
Study: 16879741

Group type: EXPERIMENTAL
Intervention: Salisbury Priority Scoring System (SPSS) used by patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salisbury Priority Scoring System (SPSS) used by surgeons
Number of subjects: 0
Study: 12622624

Group type: EXPERIMENTAL
Intervention: Narrowband UV-B (TL-01) phototherapy 3 times weekly
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral 8-methoxypsoralen photochemotherapy (8-MOP PUVA) twice weekly
Number of subjects: 54
Study: 10954911

Group type: EXPERIMENTAL
Intervention: Low-dose interferon (5 x 10(6) U thrice weekly) plus vinblastine (6 mg/m2 every 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-dose interferon monotherapy (15 x 10(6) U thrice weekly)
Number of subjects: 100
Study: 9247766

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Losartan 50 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Enalapril 10 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Enalapril 10 mg and Enalapril 20 mg
Number of subjects: 2
Study: 8325192

Group type: EXPERIMENTAL
Intervention: Transproctoscopic Doppler sonography with local sclerosing treatment (6 ml of 5% phenol almond oil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Injection of the same solution without Doppler investigation
Number of subjects: 60